Nuclera appoints Carl Raimond as Chief Executive Officer. * Former Olink Proteomics President brings extensive life-science tools leadership experience, having helped lead Olink through its $3.1 billion acquisition by Thermo Fisher Scientific * Co-founder and former CEO Dr Michael Chen transitions to Chief Scientific and Business Officer Cambridge, UK, and Boston, MA, USA, 22 September 2026: Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the appointment of Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera's co-founder and former CEO, transitions to the role of Chief Scientific and Business Officer, continuing to provide scientific leadership while supporting market development and strategic partnerships. The leadership transition marks the next phase in Nuclera's evolution as the Company builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production. The combination of Carl's experience scaling life-science businesses with Michael's scientific leadership and deep understanding of Nuclera's technology and markets will support the Company as it expands adoption of its platform across priority life-science workflows. Nuclera is applying its cell-free protein synthesis and digital microfluidics capabilities to accelerate the speed of protein science, with current focus areas including full-length IgG antibody screening, challenging membrane protein synthesis, and soluble protein expression. In May 2026, the Company launched antibody service capabilities to support early experimental triage for antibody discovery programs, complementing its eProtein Discovery(TM) system for in-house protein expression and screening. The Company is also extending its antibody strategy beyond centralized service delivery. Nuclera is advancing early partner work toward customer-site antibody screening workflows, designed to bring cell-free expression and binding triage closer to AI-enabled discovery teams and reduce the delay between computational design and experimental evidence. Carl joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition by Thermo Fisher Scientific in 2023. An experienced life-sciences executive, Carl has also held senior leadership roles at PerkinElmer, Agilent Technologies and Affymetrix. As Chief Scientific and Business Officer, Michael will focus on scientific strategy, market development and strategic partnerships, working closely with Carl as the Company enters its next phase of growth whilst maintaining continuity in Nuclera's scientific direction. Carl Raimond, CEO at Nuclera, said: "Nuclera has built a differentiated technology platform at the intersection of cell-free protein synthesis, digital microfluidics, and protein discovery. I'm excited to join the Company as we sharpen our focus on customer adoption, commercial execution, and expanding applications of our technology across life-science workflows. Michael's scientific leadership remains central to Nuclera's future, and I look forward to working with him and the team to translate this strong technology foundation into impactful solutions for our customers." Dr Michael Chen, co-founder and Chief Scientific and Business Officer at Nuclera, commented: "As a structural biologist, I know firsthand the time and frustration protein production can cost a development program. That frustration is part of why we started Nuclera. I'm incredibly proud of what the team has built and the difference our technology is already making for protein scientists. Now, we've reached an important point in the Company's evolution, and Carl is the right CEO to lead us forward. Carl's experience building and scaling life-science businesses, combined with his understanding of the opportunity ahead, will be a huge asset to Nuclera. I'm excited to work alongside him to bring that impact to every benchtop."

Nuclera launches antibody triage service to advance AI-driven antibody discovery. May 10, 2026 Rapid binder triage, of AI-driven candidate sets, enables early elimination of non-binders ahead of costly downstream workflows Powered by cell-free technology to convert AI-generated candidates into experimental binding data Cambridge, UK and Boston MA, USA 11 May 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its antibody screening service to streamline the transition from antibody hit generation to lead selection. The service will support researchers seeking to identify the most promising antibody candidates to progress to costly mammalian expression and functional testing, addressing a key bottleneck in AI-driven antibody discovery. The launch follows the Company's Series C extension[1], enabling the integration of antibody expression and binding validation to support antibody discovery workflows. Nuclera's antibody service delivers a rapid upstream triage workflow that identifies viable binders early on in the process between in silico hit generation and mammalian scale-up. By utilizing 96-plex binary cell-free expression and binding assays, the service screens full length antibody libraries in parallel, rapidly narrowing large candidate sets to a focused subset of confirmed binders. Surface Plasmon Resonance is then performed on prioritized hits for binding kinetics. Despite advances in bioinformatics and in silico antibody design, a major bottleneck remains in experimentally validating large numbers of candidates. Traditional antibody secondary screening methods are often slow and fragmented, which typically result in large amounts of resources being spent on non-binders through costly processes. As AI-driven approaches generate increasingly large antibody libraries, the need for rapid, cost-effective triage solutions has become more critical. Nuclera's antibody service addresses this gap by converting large AI-generated libraries into experimental binding data and enabling early elimination of non-binders, reserving expensive downstream biology for candidates proven to bind and accelerating progression to validated leads. Dr Michael Chen, CEO and co-founder, Nuclera, said: "Antibodies are one of the most important classes of therapeutic molecules, yet antibody discovery remains inefficient, with many initially promising candidates failing during downstream validation. A key bottleneck is the cost of recombinant antibody expression and binding validation, which limits the generation of high-quality data, and is holding back the full potential of AI/ML discovery. The launch of our antibody service addresses this challenge by enabling rapid triage of large candidate sets and delivering decision-grade binding data early in the discovery process at a competitive cost. By helping teams focus on the most promising candidates before scale-up, we are taking an important step toward enabling more effective use of AI in antibody discovery." Media contact: Dr Ben Rutter Zyme Communications Tel: +44(0)7920 770 935